[HTML][HTML] Interleukin-6: evolving role in the management of neuropathic pain in neuroimmunological disorders

K Serizawa, H Tomizawa-Shinohara, S Miyake… - Inflammation and …, 2021 - Springer
Background Neuropathic pain in neuroimmunological disorders refers to pain caused by a
lesion or disease of the somatosensory system such as multiple sclerosis (MS) and …

New BBB model reveals that IL-6 blockade suppressed the BBB disorder, preventing onset of NMOSD

…, Y Sano, H Tomizawa-Shinohara… - Neurology …, 2021 - AAN Enterprises
Background and Objectives To evaluate the pathophysiology of neuromyelitis optica
spectrum disorder (NMOSD) and the therapeutic mechanism and levels of interleukin-6 (IL-6) …

[HTML][HTML] Anti-IL-6 receptor antibody improves pain symptoms in mice with experimental autoimmune encephalomyelitis

K Serizawa, H Tomizawa-Shinohara, M Magi… - Journal of …, 2018 - Elsevier
Background and aims Chronic pain is a prevalent symptom in patients with autoimmune
encephalomyelitis such as multiple sclerosis and neuromyelitis optica. Although IL-6 is involved …

[HTML][HTML] Anti-IL-6 receptor antibody inhibits spontaneous pain at the pre-onset of experimental autoimmune encephalomyelitis in mice

K Serizawa, H Tomizawa-Shinohara, H Yasuno… - Frontiers in …, 2019 - frontiersin.org
Chronic pain is a significant symptom in patients with autoimmune encephalomyelitis, such
as multiple sclerosis and neuromyelitis optica. The most commonly used animal model of …

[HTML][HTML] Intradermal AQP4 peptide immunization induces clinical features of neuromyelitis optica spectrum disorder in mice

…, M Kurasawa, H Tomizawa-Shinohara… - Journal of …, 2023 - Elsevier
We challenged to create a mouse model of neuromyelitis optica spectrum disorder (NMOSD)
induced by AQP4 peptide immunization. Intradermal immunization with AQP4 p201–220 …

Spontaneous recovery of fear differs among early–late adolescent and adult male mice

…, S Matsuda, H Tomizawa-Shinohara… - International Journal …, 2019 - Taylor & Francis
Adolescence is a vulnerable period for developing anxiety-related mental disorders such as
post-traumatic stress disorder (PTSD), which requires a long-term course of therapy when a …

Anti-IL-6 Receptor Antibody Prevents Muscle Weakness in Experimental Autoimmune Myasthenia Gravis Mouse Model (P10-11.017)

…, M Baba, M Kurasawa, H Tomizawa-Shinohara… - Neurology, 2024 - AAN Enterprises
Objective: The objective of this study was to determine the effect of anti-IL-6 receptor
antibody on muscle weakness in experimental autoimmune myasthenia gravis (EAMG) mice. …

IL-6 blockade suppresses the blood-brain barrier disorder, leading to prevention of onset of NMOSD

…, J Nemoto, F Shimizu, Y Sano, H Tomizawa-Shinohara… - bioRxiv, 2021 - biorxiv.org
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune astrocytopathy caused
by antibodies against the aquaporin 4(AQP4) in end-feet of astrocytes. Breakdown of the …

[PDF][PDF] Cued and contextual fear memories are erased by a long passage of time after fear conditioning

…, S Matsuda, H Tomizawa-Shinohara… - 千葉医学= Chiba …, 2018 - opac.ll.chiba-u.jp
Fear memory is more stable and stronger than extinction memory itself, and is stored for a
longer period of time. However, it is unclear whether fear memory can last for a lifetime. We …

IL-6 receptor antibody treatment improves muscle weakness in experimental autoimmune myasthenia gravis mouse model

…, M Baba, M Kurasawa, H Tomizawa-Shinohara… - Frontiers in … - frontiersin.org
Myasthenia gravis (MG) is a chronic autoimmune disease characterized by muscle weakness
and fatigue. It is caused by pathological autoantibodies against components expressed at …